Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Zwipe and Wisecard join forces to drive the mass market adoption of biometric payments cards

OSLO, NORWAY– August 20[th], 2020 – Biometric fintech company Zwipe and Wisecard Technology, a leading supplier of EMV personalization and payment solutions, have partnered to support the industrialization of biometric payments solutions.                                                                                                 Headquartered in Shenzhen, China, Wisecard Technology Ltd. specializes in personalization software development, primarily focusing on the smart card payment industry. As a leading provider of EMV personalization services, the company will support the co-

Interim Financial Report - First half 2020

The first half (H1) 2020 consolidated financial statements describe the operating results of SGL TransGroup International A/S (SGL Group). · The Q2 2020 revenue was DKK 1,409m and the H1 2020 revenue was DKK 2,511m; increased by 26% vs H1 2019. · EBITDA before special items excluding IFRS 16 comprise DKK 100m for Q2 2020 and 112m for H1 2020; equal to a margin of 4,4% for H1 2020, up 1.7%-point compared to H1 2019. · SGL Group updates its 2020 guidance on EBITDA before special items (excluding the impact of IFRS 16) to be above DKK 200m. EBITDA margin before special items remains

UPM brings its first clinical product to market – FibDex® wound dressing

(UPM, Helsinki, 20.8.2020 at 10:00 EET) FibDex[®] wound dressing – made from nanofibrillar cellulose by UPM Biomedicals – has taken a significant step in its path to market, as leading medical device distributor Steripolar Oy now sells the product in Finland. FibDex is the first clinical product of renowned forest-based bioindustry company UPM and shows promising signs for future developments, such as cell therapy. ”We are excited to offer this Finnish product, made from Finnish raw material, first in the world to Finnish healthcare professionals and patients,” said Johana Kuncova-Kallio,

Scandion Oncology announces results from the next evaluable chemo-resistant colorectal cancer patient treated with SCO-101 and chemotherapy

Scandion Oncology A/S (“Scandion Oncology”) reports that the next evaluable colorectal cancer patient at the 8 weeks CT-scanning shows stable disease in the patients liver metastases, which are used to measure disease activity but a new metastatic lesion has appeared in the lung of the patient. According to the clinical protocol the patient will discontinue protocol treatment.In the first cohort of chemotherapy resistant colorectal cancer patients treated with SCO-101 and chemotherapy (FOLFIRI) we now have evaluated treatment effects on tumor size in the first two patients. One patient has

Correction interim report second quarter 2020

STOCKHOLM (August 20, 2020) – In the interim report for the second quarter of 2020 published by Starbreeze on August 18, 2020, there is a summary error regarding the line "Profit (-loss) before tax" for the second quarter of 2020. For the second quarter of 2020, the correct "Profit (-loss) before tax " amounts to SEK -8,586 thousand, "Net profit (-loss) for the period" to SEK -8,771 thousand, "Total comprehensive income for the period" to -5,814 KSEK, "Earnings per share" to -0.02 and "Profit margin,%” to -27.4. Related figures in the summaries for the first half of 2020 are correct. The

Hexagon Purus enters Northeast Asian market for hydrogen-powered passenger cars – joining the drive toward zero-emission transportation in the region

A key automotive leader for Fuel Cell Vehicles (FCEVs) in Northeast Asia has nominated Hexagon Purus, a subsidiary of Hexagon Composites, for the serial supply of composite cylinders for their current zero-emission Fuel Cell Electric SUV. Hexagon Purus‘ cylinders will be installed in the vehicle model starting by 2022. The scope of the nomination is over a two-year period with an estimated sales value of 25 million Euro. The nomination also positions Hexagon Purus for further projects within a large range of vehicle applications with this OEM. The supply contract is subject to final

Interim Report Second Quarter 2020

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO   STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2020 – 30.06.2020. The report, which has not been reviewed by the company’s auditor, is attached to this release and is available on www.stenocare.dk/investor/EN.Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “While Q2-2020 was indeed a challenging quarter for both businesses and society as a whole, we made important progress in several ways. Fully funded, with no interest bearing debt, and with our batteries charged

Meet Fable Connect – The world’s first telepresence robot for your children to stay connected with friends, school, and family

Copenhagen, August 20th, 2020Danish robotics company Shape Robotics is now extending its successful modular robotic platform, Fable, with a groundbreaking new product which adds remarkable dimensions to ordinary video chatting: Fable Connect - the world’s first telepresence robot – with lots of useful applications for families with children, the health sector and educational institutions.Fable Connect is an inventive smartphone-controlled telerobot that add amazing new dimensions to traditional video meetings, enabling families with kids and other users to keep closely connected

Cantargia publishes half year report

Cantargia AB’s (”Cantargia”) half year report for the period January until June 2020 is now available on the company’s web page www.cantargia.com/en/investors/financial-reports.Significant events in the second quarter · In April, it was announced that the ongoing COVID-19 pandemic, resulted in a three month delay of Cantargia’s CANFOUR trial. · In May, the US Food and Drug Administration (FDA) approved Cantargia’s IND application from April for the start of clinical trials in the US with CAN04 and immunotherapy. · At the 2020 AACR Annual Meeting in June, new preclinical results

Interim report January – June 2020

NET ASSET VALUE AND THE LATOUR SHARE · The net asset value fell to SEK 127 per share, compared with SEK 136 per share at the start of the year. This is a decrease of 5.5 per cent. By comparison, the Stockholm Stock Exchange's Total Return Index (SIXRX) decreased by 4.1 per cent. The net asset value was SEK 140 per share at 19 August. (1) · The total return on the Latour share was 11.5 per cent during the period measured against the SIXRX, which fell 4.1 per cent. INDUSTRIAL OPERATIONS The second quarter · The industrial operations' order intake fell 1 per cent to SEK 3,

Higher sales but lower profiability due to currency effects and increased costs

PowerCell Sweden AB increased its sales during the second quarter 2020 with 42 percent, from MSEK 15.5 to 22 due to continued large sales to Bosch and the order for a megawatt system we received from a leading European shipbuilder during the quarter. Operating income before items affecting comparability weakened to MSEK -28.3 (-16.7) due to, among other things, negative currency effects, lower gross margin, increased costs for selling and administration as well as for research and development. The Corona outbreak affected the activity level in China specifically but had no significant impact

Half-Year Report 1 January 2020 – 30 June 2020

Scandion Oncology A/S (”Scandion Oncology” or the “Company”) hereby publishes theHalf-Year Report for the period 1 January – 30 June 2020. The Half-Year Report is available on the Company's website (www.scandiononcology.com). Below is a summary of the report.Reporting period April 2020 – June 2020 · Net sales amounted to DKK 0 (0). · Operating profit was -4.75 m DKK (-4.85). · Cash and bank assets amounted to 7.28 m DKK (3.16). · Result per share was DKK -0.18 (-0.33). Reporting period January 2020 – June 2020 · Net sales amounted to DKK 0 (0). · Operating profit

MEDIVIR AB – INTERIM REPORT JANUARY – JUNE 2020

Orphan Drug designation for MIV-818 in the EU and in USAApril – JuneSignificant events during the quarter · Following the positive opinion given by the European Medicines Agency (EMA), the European Commission granted orphan medicinal product designation in the EU for MIV-818 for the treatment of patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer. · The Board of Directors appointed Yilmaz Mahshid as the new CEO of Medivir. Yilmaz Mahshid has long and broad experience from qualified roles in the life science sector. He will assume his position

Integrum AB appoints James Sheridan as Head of Sales and Marketing EMEA

Integrum, a leading provider of innovative solutions for bone anchored prosthetics, is proud to announce the appointment of James Sheridan as its Head of Sales and Marketing EMEA starting from September 1[st], 2020. As Head of Sales and Marketing, James Sheridan will be instrumental in leading Integrum´s sales and marketing team towards an accelerated expansion in EMEA. He comes to the role with more than 20 yearsof international experience working within Medical Devices in the Dental Implant Industry in markets like Australia, Japan and the Nordics. During his career he has gained

Serneke presents new business plan and announces Capital Markets Day

Serneke has set out a new business plan extending until 2025 and has adopted new long-term financial targets. The company will be holding an online Capital Markets Day on Tuesday, September 29 to present the new business plan and the strategic focus looking ahead.Having focused strongly on growth from the outset in 2002, Serneke is now conducting an extensive process on which to build the next phase in the company’s development. The new business plan sets out a clear strategy for how Serneke will focus on profitability, stability, and a continued strong corporate culture over the upcoming

Sharp deterioration in Viking Line’s results due to the impact of COVID-19

Viking Line Abp          Half-year Financial Report          20.08.2020    9.00 AM Sharp deterioration in Viking Line’s results due to the impact of COVID-19 January–June 2020 (compared to January–June 2019) · Sales amounted to EUR 97.5 M (227.0). · Other operating revenue was EUR 16.1 M (0.2). · Operating income totalled EUR -27.4 M (-8.8). · Net financial items were EUR -2.1 M (-2.2). · Income before taxes amounted to EUR -29.5 M (-11.0). · Income after taxes totalled EUR -23.7 M (-8.7). · Change in prospects: The impact of COVID-19 pandemic has continued to

RANPLAN WIRELESS

RANPLAN GROUP AB – Interim report January – June 2020 (Cision) 2020-08-20 08:00The period in summary• Total income amounted to SEK 12.2 million (30.6 million) 1• Operating results amounted to SEK -18.6 million (-1.6 million) 1• Net results amounted to SEK -20.2 million (-1.6 million) 1• Earnings per share amounted to SEK -1.01 (-0.08) 1• Cash at the end of the period amounted to SEK 10.8 million (5.1 million) 11 All comparisons are made to the first half of 2019, the numbers of which have been subject to adjustments as detailed in the Annual Report for 2019. Total income

Quarterly Report Q2-2020: First participant in the hepatic study

Ascelia Pharma AB (publ) (ticker: ACE) today published its quarterly financial report for Q2-2020 (April – June 2020), which is now available on the company’s website: https://www.ascelia.com/tag/reports-presentations/SIGNIFICANT EVENTS IN Q2-2020 · First participant enrolled in the clinical hepatic impairment study with Mangoral · Directed share issue to partly fund preparations for Mangoral market launch · Patent for Oncoral approved in Japan SIGNIFICANT EVENTS AFTER THE PERIOD · Proceeds from directed share issue received in the beginning of July FINANCIAL SUMMARY

Dignitana AB Publishes Q2 2020 Interim Report

Dignitana holds steady during challenging marketFinancial highlights · Group revenue in Q2 2020 amounted to 11 876 TSEK (12 002 TSEK), a decrease of 1 percent over the same period in 2019 and a decrease of 5 percent over Q1 2020. · EBITDA in Q2 2020 amounted to -5 066 TSEK (-5 165 TSEK), an improvement of 2 percent over the same period in 2019 and an improvement of 42 percent compared to Q1 2020. · Earnings per share in Q2 2020 is -0.17 SEK compared to -0,16 SEK in the same period 2019. · Average Daily Treatment Revenue (ADTR)* was 126 TSEK (99 TSEK), an increase of 27 percent

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during the second exercise period

Catena Media plc (Nasdaq Stockholm: CTM)  Catena Media plc (“Catena Media” or the “Company”) today announces that the second period to subscribe for shares in the Company by exercise of warrants (ticker CTM TO1) (the “Warrants) commences today, 20 August 2020.The second period to subscribe for shares in the Company by exercise of Warrants commences today, 20 August 2020, and runs up to and including 29 August 2020. During this period, each Warrant entitles the holder to subscribe for one (1) new share in the Company at a subscription price of SEK 18.90. Payment of subscribed shares can

Humana reports second quarter and half-year 2020 results

A quarter with continued focus on minimising the effects of the pandemicSecond quarter, April-June 2020 · Operating revenue was SEK 1,980 million (1,918), an increase of 3%. Organic growth was 3.4%. · Operating profit was SEK 100m (45), an increase of 123%. Capital gain of SEK 17m from sale of properties is included. Adjusted operating profit was SEK 83m (45), an increase of 84%. · Net profit after tax for the period amounted to SEK 50m (-2). · Earnings per share for the period before and after dilution amounted to SEK 0.94 (-0.04). · Operating cash flow amounted to SEK

Optomed’s January–June 2020 Half Year Report to be published on Thursday 27 August 2020

Optomed Plc        Press Release       20 August 2020 at 9.00, Helsinki Optomed’s January–June 2020 Half Year Report to be published on Thursday 27 August 2020 Optomed will publish its January–June 2020 Half Year Report on Thursday 27 August 2020 approximately at 9.00 EEST. A telephone conference for analysts, investors and media will be arranged on the publishing day at 11.00 EEST. The event will be held in English. The presentation material will be available at www.optomed.com/investors 10.00 EEST at the latest. The participants are requested to register for the call in advance

Interim Report January–June 2020

Growth outside Lidingö In early May, John Mattson took possession of the acquired apartments in Rotebro and Rotsunda in the municipality of Sollentuna. Plans to upgrade the apartments are now being developed in parallel with tangible measures carried out to improve well-being and safety in the area. In May, the company signed agreements to acquire three leasehold properties in Slakthusområdet in the City of Stockholm, with completion set for July. With these acquisitions, the company is back in the City of Stockholm and established in three municipalities in the Stockholm region. “

ISAB repositions its Contract Research business and launches “Inhalation Research Services” as new brand name

(Stockholm, 20 August 2020) Inhalation Sciences AB (ISAB) is repositioning its Contract Research business and launching it under a new brand name - Inhalation Research Services (IRS). IRS offers a comprehensive service portfolio that delivers precise and predictive early-stage respiratory research data. IRS has seen a steady increase in demand from its biopharma customers and has grown considerably during the Covid-19 pandemic.ISAB is organizing its operations into three business areas: The first is the sales of its PreciseInhale[® ]system and modules, the second is IRS, providing contract

There are no items matching the current filter
There are no more items matching the current filter
Back to top